Skip to main content
. 2022 Jan 13;231:114121. doi: 10.1016/j.ejmech.2022.114121

Fig. 1.

Fig. 1

Schematic representation of the design and development of (a) targeted nanoparticles (TNP). (b) Encapsulated model drug (remdesivir, RDV). To perform binding/upkate studies fluorescent dye (C6 or Rho) is loaded rather than the drug. (c) The PCL and PLGA-PEG blended polymeric matrix. (d) The targeting ligands (ACL, 1; DCL, 2; CPL, 3, and TACE-2, 4). The conjugation terminus site (amino or thiol functionality) for each ligand is also indicated (pale grey).